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Long-term results of the treatment of aortic graft
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Horace Spencer, PhD,a John F. Eidt, MD,a and G. Patrick Clagett, MD,b Little Rock, Ark; and Dallas, Tex
Objective:Graft excision and neo-aortoiliac system (NAIS) reconstruction with large caliber, femoral popliteal vein (FPV)
grafts have been reported as successful treatment of aortic graft infection (AGI) in several small series with limited
follow-up. The goal of this study was to evaluate long-term outcomes in large cohort of consecutive patients treated with
NAIS for AGI.
Methods: From 1990 to 2006, 187 patients (age: 63 10 years) with AGI were treated with in situ reconstructions using
336 FPV grafts. Data from a prospectively maintained data base were analyzed.
Results: NAIS reconstruction was performed for 144 infected aortofemoral bypasses, 21 infected aortic-iliac grafts, and
22 infected axillofemoral bypasses that had been placed to treat AGI. Polymicrobial cultures were present in 37% while
17% showed no growth. There were 55% gram positive, 32% gram negative, 13% anaerobic, and 18% fungal infections.
The mean Society for Vascular Surgery run-off resistance score was 4.5  2.3. Concomitant infrainguinal bypass was
necessary in 27 (14%) patients (32 limbs). Major amputations were performed in 14 (7.4%) patients. Out of 14
amputations, five patients had irreversible ischemia and in four, there was no conduit available. Graft disruption from
reinfection occurred in 10 patients (5%). While 30-day mortality was 10%, procedure-related mortality was 14%.
Independent risk factors for perioperative death on multivariate analysis were: preoperative sepsis (odds ratio [OR] 3.5)
ASA class 4 (OR 2.9), Candida species (OR 3.4), Candida glabrata (OR 7.6), Klebsiella pneumoniae (OR 3.5), and
Bacteroides fragilis (OR 4.1). Perioperative factors included use of platelets (OR 2.4), blood loss >3.0 liters (OR 9.5).
Cumulative primary patency at 72 months was 81%; secondary/assisted primary patency was 91%. Limb salvage at 72
months was 89%. Five-year survival was 52%.
Conclusions: These results compare favorably with other methods of treating AGI, especially in patients with multilevel
occlusive disease. Principle advantages include acceptable perioperative mortality, low amputation rate, superior
durability with excellent long-term patency, and freedom from secondary interventions and recurrent infections. ( J Vasc
Surg 2009;50:30-9.)Aortic graft infection (AGI) is among the most morbid
complications of vascular surgery. The primary treatment
objectives are to remove infected graft material and to
re-establish vascular continuity with an extra-anatomic
bypass or in situ graft replacement. Despite significant
progress in perioperative care and antimicrobial therapy,
mortality and morbidity remain high.
Graft excision with extra-anatomic bypass was the prev-
alent treatment in the 1980s and early 1990s and continues
to be widely practiced.1-3 More recently, in situ graft re-
placement is becoming increasingly popular because it is
expedient, avoids an aortic stump with the potential for
blowout and is associated with a low amputation rate.4,5 A
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30recent meta-analysis from pooled data demonstrated sev-
eral advantages for in situ graft replacement over extra-
anatomic bypass.6 There are currently three options for in
situ graft replacement for AGI: cryo-preserved allograft,
antibiotic soaked synthetic graft, and the autogenous fem-
oral popliteal vein (FPV) graft. In an early series with
limited follow-up, Rifampin soaked Dacron was shown to
be effective treatment for AGI with low virulent and limited
S epidermidis infections.5 Recently, two large series in
which AGI was treated with excision and in situ revascular-
ization with either cryo-preserved allograft or Rifampin-
soaked Dacron grafts have reported good results.7,8
The third option for in situ replacement is to use
femoral popliteal vein grafts. This operation, termed the
neo-aortoiliac system (NAIS) procedure represents the
only durable autogenous reconstruction. Initially reported
by Schulman9-11 as a conduit for femoral popliteal bypass,
FPV grafts were first described for AGI treatment in
1993.12 In 1997, an expanded series with moderate
follow-up was reported.13 Since then, the NAIS procedure
has been widely practiced and reported with similar results
in several small series.5,14,15
The purpose of the current study is to provide a com-
prehensive and robust, long-term follow-up in a large co-
hort of patients treated for AGI with NAIS reconstruction.
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serves to provide a realistic view of morbidity and mortality
associated with the procedure. We hypothesize that the
NAIS reconstruction is associated with acceptable morbid-
ity and mortality and offers the advantages of superior
long-term patency, durability, and freedom of secondary
interventions.
METHODS
Patient population. A retrospective review was car-
ried out for all the patients treated for AGIs from Novem-
ber 1990 to December 2006 at two tertiary care university
hospitals. All patients had been entered into a prospectively
maintained data-base. Dates for inclusion of patients from
the University of Arkansas Medical Center were from 2003
to 2006, whereas those from the University of Texas
Southwestern Medical Center spanned the entire period
and comprised more than 90% of the patients in the series.
In order to provide a fully comprehensive review of the
NAIS procedure for AGI and to note changes in outcomes
over time, the current study includes patients previously
reported.12,13,16 The prior reports contained patients un-
dergoing NAIS reconstruction for AGI and other aortic
pathology, such as mycotic aneurysm. However, only the
patients with AGI were included in the current series.
Other operations for treatment of AGI were rarely used and
only in unstable patients who could not tolerate the NAIS
procedure or in patients who did not have an adequate
FPVs. Therefore, this represents a consecutive patient series
that includes all patients treated for AGI who were eligible
for NAIS reconstruction.
Patient work-up. Noninvasive vascular laboratory
evaluation included ankle-brachial indices (ABI). Duplex
ultrasound evaluation was also used to assess the quality
and diameter of the FPV. A vein less than 6 mm in diameter
or chronically occluded FPV was not routinely used. Graft
duplex imaging has been used as an additional diagnostic
tool. The finding of a hypoechoic rim surrounding the graft
is compatible with graft infection and, in our experience,
has proved useful in the diagnosis.17 Nuclear white cell
scans were rarely used. The final diagnosis of AGI was made
during surgery and was based on purulent fluid surround-
ing nonincorporated graft. Early in the series, preoperative
workup included catheter arteriography and was later re-
placed by computed tomographic arteriography (CTA).
The arterial outflow was assessed and assigned a run-off
score according to the reporting standards on chronic limb
ischemia by the Society for Vascular Surgery (SVS).18
Operative technique. The operative technique has
been previously published.19 Since 2002, FPV valves have
been ablated under direct vision after eversion of the entire
length of the harvested vein. This change in technique
occurred because valve ablation with valvulotomes was
found to be inadequate and believed to be a source for vein
graft stenosis requiring intervention that occurred in 4.8%
of patients.20 The only other significant technical modifi-
cation has been staging the operation in a minority of cases
in this series (n  5). This approach entailed dissection ofthe FPVs at one setting, followed by vein graft harvest,
excision of the infected graft, and NAIS reconstruction one
day later, as described by Ali et al.21 In the postoperative
period, patients were routinely treated with subcutaneous
low dose heparin and calf intermittent pneumatic compres-
sion for venous thromboembolism prophylaxis.
Vein grafts were usually oriented in a nonreversed
fashion to allow the larger proximal end to be comfortably
anastomosed to the aorta. Most proximal anastomoses
were end-to-end. However, if the diameter of the aorta
greatly exceeded that of the FPV graft, a “pantaloon”
configuration was employed whereby two FPV grafts were
joined to increase the diameter of the conduit.13 Purulent
fluid, grossly infected tissue, thrombus, and graft material
were routinely cultured for bacteria and fungi by standard
microbiologic techniques.
Data collection and analysis. Charts were reviewed
for basic demographics, associated comorbidities, clinical
presentation, and culture results. Operative data included
total operative time, intravenous fluid, and transfusion re-
quirements and American Society of Anesthesiologists
(ASA) patient class. Adjunctive surgical procedures were
recorded as either vascular or nonvascular. Vascular proce-
dures included concomitant infrainguinal bypass or a
visceral/renal revascularization. Nonvascular procedures
included placement of a feeding tube, tracheostomy,
muscle flap transfer for coverage in the groin, and duo-
denal repair or bowel resection.
Patients were divided into three groups according to
the location of the infected graft: aortofemoral bypass grafts
(AFBG); aortoiliac or aortic tube graft (AIBG); and axil-
lofemoral bypass grafts (AxFBG) grafts. The latter group
represented patients who had undergone previous treat-
ment for AGI by AFBG excision and an extra anatomic
bypass.
Operative complications were divided into surgical and
medical. Surgical complications were specific to the proce-
dure such as limb loss, surgical bleeding, compartment
syndrome requiring fasciotomy, mesenteric ischemia, and
graft thrombosis. Medical complications included pneu-
monia, respiratory failure, myocardial infarction, and other
complications that might be expected to follow major
surgery.
Standard 30-day mortality was recorded. However,
because some patients died as a result of the operation later
in the hospital course, at a rehabilitation unit or at home,
we also assessed procedure-related mortality regardless of
the postoperative time span.2 ICU time and total hospital
length of stay was recorded. Information was also collected
about discharge disposition to home, rehabilitation facility,
or to a long-term skilled nursing facility.
The standard follow-up of patients who were geo-
graphically close consisted of duplex graft surveillance and
clinical examination every 4 months during the first year
and then every 6 to 12 months thereafter. If indicated,
imaging was obtained using either a conventional arterio-
gram or a CTA. For out of state patients, follow-up was
done through a telephone inquiry to the patients or the
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index was queried for all the patients who were not actively
being followed or lost to follow-up. Primary and secondary
patency and limb salvage data were defined according to
the reporting standards for the SVS.18 Graft failure was
defined as an occluded graft or stenosis requiring interven-
tion. Graft disruption or dehiscence due to nontechnical
cause was considered to be due to graft reinfection.
Data were entered into a registry using Microsoft Ac-
cess (Microsoft, Redwood, Calif). Demographic, clinical,
procedural, and postoperative variables were summarized
using means and standard deviations for continuous data,
or percentages and counts for categorical data. Themethod
of Kaplan-Meier analysis was used to estimate patient sur-
vival, graft patency, and limb salvage distributions.22 The
log-rank test was used to compare two or more survival
distributions.23 Logistic regression was used to model the
effect of demographic and medical characteristics on peri-
operative and 12-month survival. For multivariable logistic
regression models, the purposeful selection algorithm de-
scribed by Hosmer and Lemeshow was used to guide
variable selection.24 All statistical analyses were performed
using SAS version 9.1 (SAS institute Inc, Cary, NC) or R
version 2.6.2 (The R Foundation for Statistical Comput-
ing, Vienna, Austria) software.
RESULTS
Demographics. Over a 15-year period, 187 patients
were treated for AGI with partial or total removal of the
aortic prosthesis and NAIS. There were five patients lost to
follow-up after the first postoperative visit. They were not
found in the social security death index data base. All other
patients had at least a 12-month follow-up. The median
follow up was 32 (range 12-168) months. Twelve patients
were treated for AGI with either antibiotic-soaked Dacron
grafts or extra-anatomic bypass during this period. These
patients did not undergo NAIS procedure because of insta-
bility from bleeding aortoenteric fistulas or absence of
adequate FPVs. Occluded aortic grafts with tissue incorpo-
ration and negative cultures were present in 17 patients,
and these were considered noninfectious graft failure and
therefore not included in the series.
Men comprised the majority (119 [64%]) of patients
and the mean age of the entire group was 63  10 years
(median age  64 years) with a range of 29 to 88 years
(Table I). Risk factors for atherosclerosis were, as expected,
highly prevalent in this population with smoking (97%),
hypertension (92%), and coronary artery disease (56%)
being the most prominent. Of note, there was use of
systemic steroids or other immune suppressive drugs in
eight (4%) patients on presentation.
Presentation. Out of 187 patients, 140 (75%) under-
went original aortic surgery for occlusive disease, 37 (20%)
for aneurysmal disease, and 10 (5%) for both. There were
144 (77.4%) AFBG, 21 (11.2%) AIBG, and 22 (11.7%)
axillofemoral (AxFem) infections. The predominance of
occlusive disease was also reflected in the preoperative
(immediately before NAIS operation) ABIs (0.75  0.2and 0.74  0.3 in the right and left lower extremities,
respectively) and the mean SVS run-off scores (4.4  2.1
and 4.6  2.3 on the right and left sides, respectively)
(Table I). Twenty two (11.7%) patients had acute limb
ischemia on presentation and, of these, five were judged to
have irreversible ischemia and nonsalvageable limbs. The
SVS run-off score was equal to or higher than six in 47% of
patients for the right lower extremity and 48% for the left
lower extremity, respectively. Thus, there was a single vessel
(usually the profunda femoris artery) available for anasto-
mosis in nearly half of the cases.
The most common presentation was open groin
wounds (43%) followed by femoral pseudoaneurysm in
36% (Table I). Graft thrombosis and ischemia were evident
in 29%. Aortoenteric erosion/fistula (AEF) was diagnosed
in 14% of the patients. Emergency surgery was defined
where the NAIS procedure was done within 24 hours of
presentation was necessary in 11% of the patients.
Operative data. Themedian ASA score was 4 with the
Table I. Patient characteristics
Total (n  187)
Demographics
Age (y) (range) 63.2  10 (29-88)
Median (25-75 qtr.) 64 (56-72)
Men 119 (63%)
Risk factors
Smoking 179 (96%)
Hypertension 172 (92%)
Coronary disease 104 (56%)
Hyperlipidemia 73 (39%)
Diabetes mellitus 34 (18%)
COPD 24 (13%)
Renal insufficiency 17 (9%)
Steroid use 8 (4%)
End stage renal disease 3 (1.7%)
Emergency surgery 20 (11%)
On IV antibiotics 81 (43%)
Presentation
Open groin sinuses 81 (43%)
Femoral pseudoaneurysm 68 (36%)
Constitutional 61 (32%)
Weight loss (19)
Ischemia 52 (29%)
Sepsis 40 (21%)
AE erosion/fistula 26 (14%)
Bleeding 23 (12%)
Ankle-brachial index
Preoperative (right) 0.75  0.2
Preoperative (left) 0.74  0.3
SVS run-off score
Right 4.4  2.1
Left 4.6  2.6
Infected graft configuration
Aortofemoral grafts 144 (77%)
Aortic tube/iliac grafts 21 (11.2%)
Failed Ax-fem grafts 22 (11.7%)
AE, aortoenteric; AFBG, Aortofemoral bypass grafts; AIBG, aortoiliac or
aortic tube grafts; AxFBG, axillofemoral bypass grafts; COPD, chronic
obstructive pulmonary disease; IV, Intravenous.
Data reported mean  SD.mean score of 3.6 0.8.Majority (57%) of the patients had
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2.1 hours for the entire group. When both FPVs were
utilized, average operating time was 9.5  2.0. Mean
operative times for aortounifemoral and aortoiliac NAIS
were 8.1  2.4 and 7.0  1.1 hours, respectively. Average
operative blood loss was 2.6 liters requiring 7.5 units of
blood during surgery. A total of 336 of deep vein grafts
were harvested from individual limbs. In three cases, the
FPVs were inadequate and the profunda femoris veins were
used. Aortofemoral reconstructions with FPVs were per-
formed in the majority of patients (169 or 90%) and these
included aortobifemoral (105), aortounifemoral with con-
tralateral femoral crossover bypass (37), and aortounifemo-
ral bypass (no crossover bypass) (27), usually for single limb
involvement. Aortoiliac reconstructions with FPVs were
performed in only 13 patients (7%). There were five pa-
tients where the great saphenous vein (GSV) was used in
conjunction with FPV to fashion an iliac or femoral limb of
the NAIS (Table II).
Concomitant femoral popliteal or distal bypass was
required in 32 limbs of 27 (14%) patients. Right infraingui-
nal bypass with GSV was performed in 14 limbs and left
infrainguinal bypass in 18. Five patients required bilateral
lower extremity revascularization. Visceral/renal bypasses
were performed in three patients (1.6%). Twenty six
patients underwent major duodenal repair or diversion
procedures. Forty six patients (25%) had leg fasciotomy
(Table III). Most of these were earlier in the series and
were prophylactic. The rate of fasciotomy in the past 3
Table II. Operative data
Operative data Total (n  187)
ASA class
Median 4
Mean 3.6  0.8
Duration (h) 9.3  2.1
Aortobifemoral bypass 9.5  2.0
Aortounifemoral bypass 8.1  2.4
Aortoiliac bypass 7.0  1.1
Total number of grafts 336
Blood loss (L) 2.6  3.0
Transfusion blood (units) 7.5  7.1
Transfusion crystalloid (L) 6.6  4.2
Graft configurations of the NAIS
Aortofemoral 169 (90%)
Aortobifemoral 105 (56%)a
Aorto-unifem with fem-fem cross over 37 (20%)
Aortounifemoral 27 (14%)
Aortoiliac 13 (7%)
Other 5 (2.6%)c
Concomitant Fem-pop/Distal bypass (patients) 27 (14%)
Bypassb
(R) 14
(L) 18
Total limbs 32
aIncluded proximal anastomosis with a pantaloon graft.
bBilateral bypass was done in five patients.
cAortofemoral or aortoiliac configuration with femoral-popliteal vein (FPV)
and great saphenous vein (GSV) composite graft.years has declined and is currently 12%.Immediate outcomes. The 30-day mortality was 10%
and the procedure-related death rate was 14% (Table III).
Details for all deaths are listed in Table IV. The mean
length of stay was 21 8 days, however, the median length
of stay was 14 days. Out of 187 patients, 27 (14%) did not
survive, 99 (53%) were discharged home, 43 (23%) went to
a rehabilitation facility and subsequently were discharged
home, and 18 (10%) were transferred to a long-term skilled
facility.
Limb loss occurred in 14 (7.4%) patients. Five had
irreversible ischemia on presentation; four had no autoge-
nous conduit in the presence of grossly infected wounds;
two had ligation of the FPV limb as a result of postoperative
graft disruption; and one each had limb ischemia from
compartment syndrome with extensive myonecrosis, failed
distal bypass, and cardiac embolism.
Other complications are listed in Table III. Wound
complications occurred in 63 patients (34%). These in-
cluded all patients who required surgical treatment for
groin wounds and vein harvest sites that were treated with
muscle flap for coverage, incision and drainage, skin graft-
ing, and intravenous antibiotic therapy. Almost half (44%)
of these patients had a purulent groin sinus or septic
femoral wounds on presentation. Acute postoperative
bleeding occurred in 10 patients (5%) necessitating re-
turn to the operating room for control. Two patients had
acute postoperative bleeding caused by a slipped tie from
Table III. Morbidity and mortality
Total
n  187(%)
Mortality
30-day (n) 19 (10%)
Procedure related (n) 27 (14%)a
Discharge disposition
Home 99 (53%)
Rehab facility 43 (23%)
Nursing home 18 (10%)
Length of stay
(mean) 21  8
(median) 14
Surgical complications
Wound complications 63 (34%)
Fasciotomy 46 (25%)
Amputations 14 (7.4%)
Surgical bleeding 10 (5.3%)
Mesh closure (abdomen) 8 (4.3%)
Mesenteric ischemia 3 (1.6%)
Delayed graft disruptions 10 (5.3%)
Medical complications
Pulmonary 25 (13%)
Tracheostomy 17 (9%)
Acute renal failure 22 (12%)
Coagulopathy 22 (12%)
Myocardial infarction 8 (4.3%)
Stroke 3 (1.6%)
Paralysis 3 (1.6%)
Pulmonary embolism 2 (1.1%)
aProcedure related mortality includes death beyond 30 days.one of the FPV grafts.
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Age/Sex/Presentation ASA Surgical procedure Graft microbiology Complications Terminal event
75/F AIBG for AAA
GI bleed from AEF
4E Aortoiliac Candida species
Pseudomonas a
Duodenal leak Died on POD #34 from
MSOF
77/F AFBG for occl
AEF groin sinuses
4 Aortoiliac, SMA
bypass
Staph epi Mesenteric ischemia,
splenic bleeding
Bowel ischemia, fungal
sepsis
Died on POD #27
72/M w AIBG for AAA.
AEF w GI bleed
4E Aortoiliac Klebsiella pneumoniae,
Candida glabrata,
Bacteroides f.
Paraplegia, MSOF Died POD #42 MSOF
55/F Infect AX-FEM for
AFBG infection,
retroperitoneal abscess
3 Aortobifemoral MRSA Intraoperative cardiac
arrest due to bleeding
Died POD #2
53/M AFBG sepsis and
ketoacidosis
4 Aortobifemoral Gp B Streptococcus
Staph aureus
Lower extremity ischemia Died on POD #14 from
myocardial infarction
(autopsy)
69/F AFBG and a fem-
fem, graft thrombosis,
groin sinus, AEF
4 Aortounifemoral
aortoiliac
Candida glabrata,
Klebseilla pneumoniae
Duodenal leak Died on POD #61, graft
disruption requiring
ligation with
amputation
70/M AFGB (AAA) with
graft-colonic erosion,
on steroids for COPD
4 Aortobifemoral,
colectomy,
Candida tropicalis,
Candida glabrata
Respiratory, renal failure,
sepsis
Died on POD #12 from
MSOF
75/M AFBG (AAA)
sepsis, febrile
3 Aortobifemoral Enterobacter c. MRSE Possible intraop ligation of
splenic vein
Died on POD #6 from
splenic rupture
(autopsy)
81/M AIBG (AAA)
aortic pseudoaneurysm
4 Aortobi iliac, Salmonella, Yeast,
MRSE
Sepsis, pancreatitis, Died on POD #24
MSOF
69/F AFBG (occl) AEF
w bleeding, sepsis
4E Aortounifemoral,
Colon resection,
Klebsiella pneumoniae,
E coli Cand
albicans,
Perioperative graft
thrombosis, bilateral hip
disarticulations
Died on POD #48
MSOF
70/F AFBG (AAA) groin
sinus
3 Aorotbifemoral Bacteroides f. Candida
species
Groin wound infections Died on POD #57 from
distal graft disruption
61/M AFBG (occl) groin
sinuses, active TB
4 Aortobifemoral,
pericard window
No data available Intraop cardiac arrest,
Abdomen closure w/
mesh,
Died on POD #24 from
MSOF
56/F AFBG/Fem-fem
(occl) groin sinus,
ischemia
4 Aortounifemoral,
fem-fem, fem-pop
w GSV
Klebsiella p, E coli,
MRSA,
Pseudomonas
Compartment syndrome
resulting in bilateral
amputations, Reinfection
Graft disruption on
POD #57 requiring
ligation. Died shortly
after
65/F Ax-FEM (occl)
groin sinus
4 Aortounifemoral,
Fasciotomy
No growth Mesenteric ischemia from
acute SMA thrombosis
Died on POD #8 from
mesenteric ischemia
73/M AFBG
(AAAoccl) AEF w GI
bleed, sepsis
4E Aortobifemoral,
Duodenal resection
Candida glabrata,
Albicans, Strep Sp.
Wound infections,
respiratory failure,
coagulopathy
Died on POD #37
MSOF
72/M Aortic (AAA)
aortic pseudoaneurysm
4 Aortoiliac, correct
midgut volvulus
Candida glabrata,
MRSE
ARF, mesenteric ischemia,
surgical bleeding
Died on POD #26 from
mesenteric ischemia
76/M AFBG (occl) Fem
pseudo aneurysm
3 Aortobifemoral,
fasciotomy
No growth Massive surgical bleeding,
coagulopathy, Abdomen
closure w/mesh
Died on POD #35
MSOF
66/M AFBG (occl)
ischemia, groin sinuses
4 Aortobifemoral, Propionibacter ARF, respiratory failure,
Abd mesh closure
Died on POD #28 from
MSOF
76/M AFBG (occl),
bleeding femoral
pseudoaneurysm,
cirrhosis
4E Aortobifemoral,
tracheostomy
Enterobacter, Strep Sp.
Bacteroides f.
Coagulopathy, liver failure, Died from coagulopathy
on POD #2
70/M AFBG (occl) AEF
w GI bleeding, sepsis
4E Aortofem, fem-fem,
Fem-pop w GSV,
Fasciotomy,
duodenal resection
Candida glabrata,
Lactobacillus
Lower extremity ischemia,
leak from the duodenal
repair
Died on POD #16 from
graft disruption w
recurrent AEF
66/M AFBG (occl) Graft
thrombosis, ischemia
4 Aortobifemoral,
splenectomy
Serratia M (2 strains)
MRSE
Respiratory failure, Cardiac arrest on POD
#12, anoxic brain
injury
60/F AFBG (occl),
febrile, sepsis
3 Aortobifemoral, bilat.
Fem-pop w/GSV,
Staph epidermidis Wound infection requiring
multiple wound
Died on POD #16 from
MSOF, malnutritionFasciotomy debridments
y; Pse
dermi
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There were five proximal (intra-abdominal) disruptions and
five distal (femoral) disruptions. These have been previ-
ously reported.25 Most of the graft disruptions occurred
within the first 2 weeks after NAIS. We attribute this to
reinfection but this was documented in only a few of these
patients. One patient treated with aggressive immunosup-
pression had a graft disruption at 7 months caused by
recurrent infection surrounding the aortic anastomosis.
The majority (6 out of 10) had initial presentation with an
AE fistula or erosion. Five out of six had documented
duodenal leaks after repair of the duodenum. Some of the
patients with graft disruption had severe malnutrition with
nonhealing femoral wounds and exposed FPV grafts. All
the patients with graft disruptions had polymicrobial infec-
tions (Table IV). Only four out of 10 patients survived graft
disruption.
The most common medical complication was pulmo-
nary failure requiring ventilator support for extended pe-
riod of time (Table III). Of these, 17 patients (9%) required
a tracheostomy. Acute renal failure occurred in 22 patients
(12%) who required temporary hemodialysis. The rate of
lower extremity paralysis was 1.6% (three patients) and all
of these occurred early in the series.13 There have been no
cases of paralysis in the last 140 consecutive patients.
Microbiology. There was no information available on
seven (4%) patients. Polymicrobial cultures were present in
37% while a single organism was identified in 45% of the
cases. Gram positive organisms were most prevalent, 55%.
Fungal cultures were present in 17%, and anaerobic infections
were present in (14%). There were 17% of patients where no
Table IV. Continued
Age/Sex/Presentation ASA Surgical procedure Graft
75/F AFBG, Ax-fem
(occl) with groin sinus,
ischemia
4 Aorotfemoral, fem-
fem, Subclavian
bypass
Klebseill
Cand
Enter
55/F AFBG (occl) graft
thrombosis, ischemia
3 Aortobifemoral No grow
81/M AIB (AAA)
femoral
pseudoaneurysm
bleeding
4 Aortoiliac Not ava
79/M AFBG (occl) AEF,
sepsis
4E Aortofem, fem-fem,
Duodenal resection
Pseudom
Enter
Cand
69/F Aortic graft( AAA)
Psoas abscess
4 Aortoiliac,
splenectomy
Bacteroi
Enter
AAA, abdominal aortic aneurysm; AEF, aortoenteric fistula/erosion; AIBG
graft; Bacteroides f, Bacteroides Fragilis; E, emergency; E.coli, Escherichia co
GI, gastrointestinal; Gp B, Group B; Klebsiella P, Klebsiella pneumonia
Multisystem organ failure; Occl, occlusive disease; POD, postoperative da
Marcescens; SMA, superior mesenteric artery; Staph epi, Staphylococcal Epiorganism was identified on final cultures (Table V).Long-term outcomes. Patency, limb salvage, and
overall survival data are presented in Figs 1, 2, and 3. At 72
months, the primary and assisted/secondary patency were
81% and 91%, respectively (Fig 1). Limb salvage was 89%
at 7 years (Fig 2). All amputations during long-term
follow-up occurred because of progression of distal occlu-
sive disease. Overall survival at 5 years was 52% with most
patients dying of cardiovascular disease (Fig 3). Patients
who presented with AE fistula did worse compared with
those without AE fistula for perioperative period and on
long term follow-up (log-rank P  .006, Fig 4).
Multivariate independent predictors of death or poor
out come were reported for the immediate, perioperative
period and 12 months after surgery (Table VI). The
perioperative factors included microorganism: Candida
species with Candida glabrata in particular, Klebsiella
pneumoniae, and Bacteroides fragilis infections. Addi-
Table V. Microbiology
No growth 31 (17%)
Single organism 81 (45%)
Multiple organism 67 (37%)
No data available 7 (4%)
Data available 180 (96%)
Typea
Gram positive 100 (55%)
Gram negative 57 (32%)
Anaerobes 24 (13%)
Fungal 32 (18%)
aMutually exclusive with more than one type of bacteria was cultured in 37%
of the patients.
biology Complications Terminal Event
umoniae,
abrata,
s MRSE
Abdominal sepsis,
hematoma, liver failure
Died on POD #23 from
sepsis
Surgical bleeding from
postop, heparin for
mitral valve
Cardiac arrest on POD
#15
Pt. had metastatic liver
cancer
Died on POD #8 from
liver failure
a.,
r c.,
lbicans
Duodenal leak, sepsis,
ARF,
Graft disruption
requiring ligation.
Died on POD #19
from myocardial
infarction
r c.
Graft disruption POD #11,
requiring FPV ligation
and fem-fem bypass
renal, respiratory failure
Died on POD #16
MSOF,
oiliac bypass; ARF, acute renal failure; AXFemBG, axillary-femoral bypass
terobacter C, Enterobacter Cloacae; F, female; FPV, femoral popliteal vein;
male; MRSE, Methicillin resistant Staphylococcal Epidermidis; MSOF,
udomonas a, Pseudomonas Aeruginosa; Pt, Patient; Serratia M, Serratia
dis; Strep Sp, Streptococcal species.micro
a pne
ida gl
ococcu
th
ilable
onas
obacte
ida a
des f.,
obacte
, aort
li; En
e; M,tionally, perioperative sepsis was a predictor of poor
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when the blood loss was greater than 3000 mL, which
was probably indicative of the difficulty of the procedure.
Factors associated with poor 12-month survival were
Age 64 (OR 3.3 P  .005), initial presentation with
proximal or distal anastomotic bleeding (OR 2.8 P 
.01), chronic renal insufficiency (OR 3.3 P  .004),
fungal infection (OR 3.1, P  0.01) and ASA class 4 or
higher (OR 5.3 P  .001) (Table VI). Patients with no
Fig 1. Primary and assisted primary/secondary patency. The pa-
tencies is 81% and assisted primary/secondary patency is at 91%
with standard error at 5%. The numbers at risk are noted at each
time point.
Fig 2. Limb salvage. Limb salvage rate is 89% at 7 years. The
numbers of limbs at risk are noted at each time point. The standard
error (in parentheses) at 7 years is 3.1%.growth on culture of graft and purulent material hadbetter outcomes with a 6% perioperative mortality and a
1 year survival of 87%.
DISCUSSION
This study confirms the theoretical advantages of the
NAIS procedure for AGI. Autogenous FPV grafts have
unique features that include large caliber, infection resis-
tance, and nonthrombogenic surface that make them an
ideal conduit for large arterial reconstructions. On long-
Fig 3. Survival. The survival at 5 years is 52.4%. The numbers at
risk are noted at each time point. Standard error (in parentheses) at
6 years is 10%.
Fig 4. Survival for patients with aortoenteric (AE) fistula. Survival
differed significantly between patients with and without AE fistula
(18.4% vs. 56.7%). Standard errors (in parentheses) exceeded 10%
at 7 years for patients without AE fistula and all time points for
patients with AE fistula.term follow-up, we have demonstrated a primary and as-
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tively. These patencies were achieved in patients with
multilevel occlusive disease and poor run off without ad-
junctive, aggressive antithrombotic therapy. Most of our
NAIS patients are treated with aspirin as part of general
medical treatment for cardiovascular disease. Only a few are
treated with vitamin K antagonists or clopidogrel for other
specific cardiac or venous indications. Despite AGI with a
wide variety of virulent gram-positive, gram-negative and
fungal infections, life-long or even long-term antibiotic
therapy beyond 4 to 6 weeks has also been found to be
unnecessary.
Durability is also realized because FPV grafts have a low
incidence of developing vein graft stenosis, most likely
because of their large caliber.20 We were initially concerned
about the potential for aneurysmal degeneration, but this
has not occurred in our NAIS experience. The potential for
chronic venous morbidity after removal of FPVs was also
feared. However, we have documented minimal distur-
bance of venous physiology on long-term follow-up and
fewer than 15% of limbs had evidence of significant chronic
venous morbidity (CEAP Class C3-C5) on clinic examina-
tion at amean follow-up of 70months.26,27 In that study, we
described two limbs with more advanced venous morbid-
ity. One limb had brawny edema (CEAP Class C4) and one
limb with a healed ulceration (CEAP Class C5). To date,
those two limbs are the only limbs with CEAP Class C4 or
greater venous morbidity in over 400 limbs from which
FPV has been harvested for a variety of operations at our
institutions. Although early postoperative swelling of har-
vested limbs is common, swelling typically subsides over
the ensuing weeks. It is rare that we need to prescribe
compression stockings at late follow-up of patients after
FPV harvest. In addition to NAIS procedures for AGI,
we and others have demonstrated the beneficial features
of this large caliber vein graft in multiple vascular
Table VI. Predictors of mortality
Perioperative Odds ratio P value
Organisms (graft)
Cand. Glabrata 7.6 .01
Klebsiella P 3.5 .04
B Fragilis 4.1 .04
Fungal 3.4 .02
Preoperative sepsis 3.5 .02
Blood loss  3000 mL 9.5 .001
ASA class 4 2.9 .02
Platelet transfusion 2.4 .01
12-month
Age 64 3.3 .005
ASA class 4 5.3 .001
Fungal graft infection 3.1 .01
CRI 3.3 .004
Initial presentation with bleeding 2.8 .01
Preoperative sepsis 2.0 .04
CRI, Chronic renal insufficiency.
Fungal etiology was an independent risk factor in addition to Candida
glabrata.beds.9,28-31Acute venous morbidity resulting in the need for fas-
ciotomy remains a problem with harvesting FPVs in some
patients. In a previous report, we demonstrated that pre-
existing advanced lower extremity ischemia, concomitant
harvest of ipsilateral GSV, and excessive crystalloid admin-
istration during operation were independent risk factors for
compartment syndrome and the need for fasciotomy.32
The overall rate of fasciotomy in the current series was 25%.
This high rate was due to multiple factors. Most of the
fasciotomies were prophylactic and not due to the develop-
ment of compartment syndrome. They were carried out at
the end of the NAIS procedure because of asymmetric calf
fullness or other subjective findings. Although we generally
have a low threshold to perform fasciotomy at our institu-
tion, it is the senior author’s opinion that many of the
fasciotomies in this series were unnecessary. It is notewor-
thy that no fasciotomies were performed in the series of
NAIS reconstructions for AGI reported by Nevelsteen
et al.14,15
Other factors that contributed to the high rate of
fasciotomy in this series were that most of the patients had
occlusive disease (many had advanced ischemia) and that
anesthetic techniques rooted in a philosophy of administer-
ing large amounts of crystalloid were prevalent earlier in the
series. We have recently demonstrated an overall reduction
in complications following the NAIS operations by restrict-
ing the amount of intravenous crystalloids administered.33
The rate of fasciotomy has declined in recent years to
approximately 12%, and this is most likely due to improved
anesthetic techniques and more stringent criteria for the
performance of fasciotomy.
Much has been made of the postulate that the NAIS
procedure is long, technically demanding, and may require
two teams. At our institution, we perform this operation
with a single team that most often consists of the attending
surgeon, vascular fellow, a second or third year general
surgery resident, and a medical student. As we document in
this report, the operation is long taking 7 to 11 hours on
average. This could possibly be shortened with two separate
surgical teams (one harvesting veins while the other excises
the aortic graft); however, we have not found this necessary
or feasible in our practice. Ali et al recently reported short-
ening the NAIS operation by staging FPV harvest.21 The
femoral veins are dissected and left in situ and the aortic
graft excision and NAIS reconstruction are carried out 24
hours later.
As far as the technical demands, they are well within the
capability of a well-trained vascular surgeon. Throughout
our experience, we have noted no “learning curve” in
performing this operation. It is noteworthy that our overall
mortality has not decreased over time. In fact, it has actually
increased. In our previous report, the mortality for NAIS
for AGI was 8% and currently it is 10% for 30-day mortality
and 14% for procedure-related mortality. This change most
likely reflects the more realistic appraisal of mortality that is
realized with a larger, more robust series. In addition, we
have subjectively noted that referral of sicker patients has
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treating these patients.
The identification of independent risk factors for death
after NAIS is of interest. Some are obvious such as massive
blood loss, renal failure, high ASA score, and preoperative
sepsis (Table VI). Infections with Candida glabrata, Kleb-
siella pneumoniae, and Bacteroides fragalis are more puz-
zling. Others have noted poor outcomes with Klebsiella
infections as well.8 Anaerobic infections have may be more
deadly because these organisms were usually part of
polymicrobial infections that are frequently associated with
sepsis, debilitation and severe systemic toxicity. The same is
true for Candida glabrata infections. Patients with Can-
dida infections in our series generally had a prolonged
course of medical therapy with multiple antibiotics prior to
referral and suffered from chronic sepsis, malnutrition, and
debilitation.Candida glabratawas also frequently found in
patients with AE fistula, which was associated with a poor
outcome (Fig 4).
Recurrent or persistent infection was judged to have
been the etiology in the graft disruptions that occurred
in 5% of the patients in this series. This is a severe
problem in that two-thirds of the patients with graft
disruption died from this complication. This is disap-
pointing but not surprising. We have previously reported
that graft disruption of FPV grafts occurs in the setting
of ongoing contamination of the graft, severe malnutri-
tion, immunosuppression and debilitated state.25 In the
10 patients with disruption, six had AE fistula or erosion.
Five of these six patients had had persistent leakage of
enteric contents that was contiguous with FPV grafts.
Severity of infection is also a contributing factor since all
patients with graft disruption had polymicrobial infec-
tions. Although FPV grafts are infection resistant, this
benefit is realized in patients with intact host defenses
and in which there is only temporary contamination of
the bed where the vein graft is placed.
Patients with AE fistula represent a subset with espe-
cially poor outcomes, regardless of the surgical approach.
In the current study, patients with an AE fistula had a
higher mortality rate after NAIS reconstruction than pa-
tients without an AE fistula (Fig 4). Our group recently
reported our experience with AE fistulas using a variety of
approaches, including extra-anatomic reconstruction with
aortic stump ligation and NAIS reconstruction.34 There
was no difference in mortality based on the surgical ap-
proach. In that series, the only independent predictors of
mortality were age and gastrointestinal complications. As
noted in the current study, five of six patients with AE
fistulas who experienced graft disruption had duodenal
leaks that bathed the vein graft in gastrointestinal luminal
contents. This experience provides further evidence that
the integrity of the duodenal reconstruction is the primary
determinant of outcome, rather than the type of recon-
struction or conduit. To minimize the risk of a duodenal
leak, we now obtain the assistance of our gastrointestinal
surgeons for multilayer closure of the duodenum and se-
lective duodenal diversion. Whenever feasible, we utilizeomentum for meticulous exclusion of the duodenal repair
from the NAIS reconstruction or aortic stump. We cur-
rently advocate selecting the type of reconstruction for AE
fistulas based on several factors, including the stability of
the patient, the length of the aortic stump, and our confi-
dence in the duodenal reconstruction. A NAIS reconstruc-
tion is not a reasonable option for unstable patients, but
may be the most appropriate reconstruction if there is
insufficient length of infrarenal aorta for a multilayered
aortic stump closure.
We previously reported discontinuing antibiotics 5 to 7
days after NAIS for AGI but we now recommend continu-
ing antibiotic therapy for 4 to 6 weeks in patients with
anaerobic, gram negative, and fungal infections. In patients
with these infections who are severely malnourished, debil-
itated, and immunosuppressed, we will consider alternative
procedures such as extra-anatomic bypass.
In our series of NAIS reconstructions, the outcome for
patients with no growth on culture of the excised graft was
better than the larger cohort, including perioperative mortal-
ity of 6% and 1-year survival of 87%. We attribute the im-
proved outcomes for this group to probable infection with
low virulence organisms that did not growon standard culture
techniques. Others have advocated using antibiotic-soaked
Dacron grafts for selected patients with limited, low
virulence infections. This is clearly a more expedient
operation and has reported low short-term mortality and
amputation rate. However, the uncertain risk of re-
infection and the requirement for life-long antibiotic
therapy limit the usefulness of this approach. The series
reporting treating AGI with antibiotic-soaked Dacron
grafts are not comparable to ours because they are small,
have limited follow-up and have a relative paucity of
patients with infected AFBGs who have multilevel occlu-
sive disease with poor run off.4,5,8 For example, in the
report from the Mayo clinic, less than half of the patients
presented with infected AFBGs.8 Most had limited in-
fections of low virulence with minimal, purulent contam-
ination. We agree that antibiotic-soaked Dacron grafts
have a role in the management of AGI and use this in
highly selected who are too unstable to undergo NAIS
reconstruction. This is usually in the setting of massive
gastrointestinal bleeding from aortoenteric fistula. The
50% survival of patients at 5 years who were cured of AGI
(Fig 2) is sobering. When presented with a patient with a
limited life span, we now consider this option.
For the majority of patients with AGI, we continue to
advocate the NAIS reconstruction because of its superior
durability in comparison to other procedures. These pa-
tients do not require lifelong antibiotic therapy. They also
have an excellent outlook for limb salvage. The risk of
reinfection is low, as is the need for reintervention for vein
graft stenosis.
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